BioPlus Signs Joint Development Agreement with Procell Therapeutics for Next-Generation Botulinum Toxin and More

[Asia Economy Reporter Lee Gwan-joo] BioPlus announced on the 28th that it has signed a joint development agreement with Procell Therapeutics, a company specializing in recombinant proteins and drug delivery systems, for the development of a "next-generation botulinum toxin" and an oral diabetes and obesity treatment using bio-better materials of liraglutide.

Under this agreement, the two companies plan to first develop a highly stable next-generation light-chain botulinum toxin by combining protein recombination and effective drug delivery technology (MTD).

To this end, they will collaborate throughout the entire process from the development of next-generation botulinum toxin raw materials and formulations to preclinical, clinical, regulatory approval, distribution, and sales. Procell Therapeutics will be responsible for developing core active substances such as light-chain botulinum toxin and drug delivery systems, while BioPlus will handle formulation development, material production, clinical trials, regulatory approval, and sales.

Additionally, they will jointly develop treatments for diabetes and obesity. By combining the bio-better material of liraglutide (the active ingredient of Saxenda) with an extended half-life, jointly developed by BioPlus and its subsidiary UbiProtein, and Procell Therapeutics' drug delivery system that improves intestinal membrane permeability, they aim to develop an improved oral formulation drug that enhances dosing convenience compared to the currently marketed once-daily injectable therapy.

Jung Hyun-kyu, Chairman of BioPlus, stated, "Through joint research between the two companies, each possessing useful materials and delivery technology, we expect to create high synergy. We anticipate introducing effective treatments applicable to various diseases, including a safe 'next-generation botulinum toxin' widely usable in chronic disease treatments such as chronic headaches, migraines, and tic disorders, as well as in the field of skin beauty, and an oral diabetes and obesity treatment using improved liraglutide materials with enhanced convenience and stability."

This content was produced with the assistance of AI translation services.